SenzaGen has signed a global licensing agreement with Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD™ test to its clients. 

GARD™ is a genome-based test, with higher accuracy than other available test methods that gives the customers important safety information whether chemical substances are at risk of causing allergies in humans.

Eurofins BPT is the largest network of harmonized bio/pharmaceutical GMP/GLP product testing laboratories worldwide with 30 facilities all over the world, providing comprehensive laboratory services for the world’s major pharmaceutical, biopharmaceutical and medical device companies. The Munich subsidiary of Eurofins BioPharma Product Testing was part of the successful ring trial in the validation of GARDskin™, which was completed in late 2017.

Under the terms of the agreement, Eurofins BPT Munich will immediately include GARDskin™ and the add on test GARDpotency™ as a leading diagnostic tool in its chemical safety testing services to clients in the cosmetic, chemical and pharmaceutical industries worldwide. 

“This new license agreement with such a major and strong partner provides an important stepping stone in the global marketing of GARD and it is also a hallmark of the high quality and relevance of GARD. We are very pleased to sign this important deal, in particular since Eurofins BPT Munich is a leading player in chemical safety testing, with a pronounced mission to contribute to global health and safety,” says SenzaGen’s chief executive officer, Anki Malmborg Hager.